Additional File 8 of IRGS: an Immune-Related Gene Classifier for Lung Adenocarcinoma Prognosis

Xiaoshun Shi,Ruidong Li,Xiaoying Dong,Allen M. Chen,Xiguang Liu,Daru Lu,Siyang Feng,He Wang,Kaican Cai

DOI: https://doi.org/10.6084/m9.figshare.11805717

2020-01-01

Abstract:Additional file 8: Table S5. Significantly enriched immune pathways of gene in the IRGS model.

What problem does this paper attempt to address?

Additional File 2 of IRGS: an Immune-Related Gene Classifier for Lung Adenocarcinoma Prognosis

Xiaoshun Shi,Ruidong Li,Xiaoying Dong,Allen M. Chen,Xiguang Liu,Daru Lu,Siyang Feng,He Wang,Kaican Cai

DOI: https://doi.org/10.6084/m9.figshare.11805678

2020-01-01

Abstract:Additional file 2: Table S1. Differentially expressed genes in the TCGA-LUAD dataset.
Additional File 1 of Integration of Single-Cell Regulon Atlas and Multi-Omics Data for Prognostic Stratification and Personalized Treatment Prediction in Human Lung Adenocarcinoma

Yi Xiong,Yihao Zhang,Yu Yao,Yueshuo Li,Hongwei Liu,Qian Yang,Yu Chen,Xia Zhang,Xin Chen,Siyi Wanggou,Xuejun Li

DOI: https://doi.org/10.6084/m9.figshare.23751836

2023-01-01

Abstract:Additional file 1: Table S1. Basic information of included datasets. Table S2. Identification of prognostic regulons. Table S3. LPRI of all included datasets.
Identification of Immune-Related Gene Signature for Non-Small Cell Lung Cancer Patients with Immune Checkpoint Inhibitors

Li Wang,Chaonan Han,Chenlei Cai,Jing Wu,Jianing Chen,Chunxia Su

DOI: https://doi.org/10.1016/j.heliyon.2024.e26974

IF: 3.776

2024-01-01

Heliyon

Abstract:BackgroundThe utilization of immune checkpoint inhibitors (ICIs) has become the established protocol for treating advanced non-small cell lung cancer (NSCLC). This work aimed to identify the immune-related gene signature that can predict the prognosis of NSCLC patients receiving ICI treatment.MethodsThe ImmPort database was queried to obtain a list of immune-related genes (IRGs). Differentially expressed IRGs in NSCLC patients were identified using the TCGA database. RNA-seq data and clinical information from NSCLC patients receiving immunotherapy were obtained from the GEO database (GSE93157 and ////). A gene signature was generated through multivariate Cox and LASSO regression analyses. The prognostic value and function of this gene signature were thoroughly investigated using comprehensive bioinformatics analyses.ResultsA total of 6 prognostic-related genes were identified from 617 differentially expressed genes, and two prognostic-related differentially expressed genes (CAMP and IL17A) were determined to construct gene signature. Our gene signature demonstrated superior performance compared to other clinicopathological parameters in predicting the prognosis of NSCLC patients receiving immunotherapy, with an area under the ROC curve (AUC) of 0.812. Furthermore, immune infiltration analysis indicated that the high-risk group was enriched with resting CD4 T cell memory, while the low-risk group showed a "hot" tumor microenvironment that promotes anti-tumor immunity in NSCLC patients.ConclusionGene signatures based on immune-related genes exhibited excellent indicator performance of prognosis and immune infiltration, which has the potential to be an effective biomarker for NSCLC with ICI treatment.
Prognostic Risk Model of Immune-Related Genes in Colorectal Cancer

Yucheng Qian,Jingsun Wei,Wei Lu,Fangfang Sun,Maxwell Hwang,Kai Jiang,Dongliang Fu,Xinyi Zhou,Xiangxing Kong,Yingshuang Zhu,Qian Xiao,Yeting Hu,Kefeng Ding

DOI: https://doi.org/10.3389/fgene.2021.619611

IF: 3.7

2021-01-01

Frontiers in Genetics

Abstract:PurposeWe focused on immune-related genes (IRGs) derived from transcriptomic studies, which had the potential to stratify patients’ prognosis and to establish a risk assessment model in colorectal cancer.SummaryThis article examined our understanding of the molecular pathways associated with intratumoral immune response, which represented a critical step for the implementation of stratification strategies toward the development of personalized immunotherapy of colorectal cancer. More and more evidence shows that IRGs play an important role in tumors. We have used data analysis to screen and identify immune-related molecular biomarkers of colon cancer. We selected 18 immune-related prognostic genes and established models to assess prognostic risks of patients, which can provide recommendations for clinical treatment and follow-up. Colorectal cancer (CRC) is a leading cause of cancer-related death in human. Several studies have investigated whether IRGs and tumor immune microenvironment (TIME) could be indicators of CRC prognoses. This study aimed to develop an improved prognostic signature for CRC based on IRGs to predict overall survival (OS) and provide new therapeutic targets for CRC treatment. Based on the screened IRGs, the Cox regression model was used to build a prediction model based on 18-IRG signature. Cox regression analysis revealed that the 18-IRG signature was an independent prognostic factor for OS in CRC patients. Then, we used the TIMER online database to explore the relationship between the risk scoring model and the infiltration of immune cells, and the results showed that the risk model can reflect the state of TIME to a certain extent. In short, an 18-IRG prognostic signature for predicting CRC patients’ survival was firmly established.
Assessing the Prognostic Capability of Immune-Related Gene Scoring Systems in Lung Adenocarcinoma

Wenhao Liu,Ruihong Dong,Shuai Gao,Xiaodi Shan,Mian Li,Zhaoyan Yu,Liang Sun

DOI: https://doi.org/10.1155/2022/2151396

IF: 4.501

2022-08-01

Journal of Oncology

Abstract:Background. Lung adenocarcinoma (LUAD) is the commonest of the subtypes of lung cancer histologically. For this study, we intended to analyze the expression profiling of the immune-related genes (IRGs) from an independently available public database and developed a potent signature predictive of patients' prognosis. Methods. Gene expression profiles and the clinical data of lung adenocarcinoma were gathered from the Gene Expression Omnibus database (GEO) and The Cancer Genome Atlas (TCGA), and the obtained data were split into a training set (n = 226), test set (n = 83), and validation set (n = 400). IRGs were then gathered from the ImmPort database. A prognostic model was constructed by analyzing the training set. Then the GO and KEGG analysis was performed, and a gene correlation prognostic nomogram was constructed. Finally, external validation, such as immune infiltration and immunohistochemistry, was performed. Results. The 110 genes were significant by univariate Cox regression analysis and randomized survival forest algorithm for the training set and showed a good distinction between the low-risk-score and high-risk-score groups in the training set ( P < 0.0001 ) by screening for four prognosis-related genes (HMOX1, ARRB1, ADM, PDIA3) and validated by the test set GSE30219 ( P = 0.0025 ) and TCGA dataset ( P = 0.00059 ). Multivariate Cox showed that the four gene signatures were an individual risk factor for LUAD. In addition, the genes in the signatures were externally verified using an online database. In particular, PDIA3 and HMOX1 are essential genes in the prognostic nomogram and play an important role in the model of immune-related genes. Conclusion. Four immune-related genetic signatures are reliable prognostic indicators for patients with LUAD, providing a relevant theoretical basis and therapeutic rationale for immunotherapy.

oncology
Additional File 8 of Immune-related Long Non-Coding RNA Signature Identified Prognosis and Immunotherapeutic Efficiency in Bladder Cancer (BLCA)

Rui Cao,Lushun Yuan,Bo Ma,Gang Wang,Ye Tian

DOI: https://doi.org/10.6084/m9.figshare.12577466

2020-01-01

Abstract:Additional file 8: Table S3. Summary of ssGSEA scores for hallmark gene sets in TCGA-BLCA cohort.
Immune-related Gene Signature in Predicting Prognosis of Early-Stage Colorectal Cancer Patients.

Jia Ke,Xuan-hui Liu,Xiao-feng Jiang,Zhen He,Jian Xiao,Bin Zheng,Yu-feng Chen,Ze-rong Cai,Xiao-bin Zheng,Yi-feng Zou,Ping Lan,Xiao-jian Wu,Feng Gao

DOI: https://doi.org/10.1016/j.ejso.2020.08.008

IF: 4.037

2020-01-01

European Journal of Surgical Oncology

Abstract:3586 Background: Immune-related genes (IRGs) were found to be associated with the prognosis of colorectal cancer (CRC) patients. The aim of this study was to evaluate the impact of IRGs in predicting prognosis of early-stage CRC patients. Methods: According to the CIT microarray data set, 309 early-stage CRC patients were selected for generation of immune-related gene signature (IRGS). 5 independent data sets included 1587 CRC patients with complete prognostic information were divided into a training cohort (566 patients) and two validation cohorts (624 patients in validation-1 and 397 patients in meta-validation). Prognostic analysis were performed to test the predictive value of IRGS. Results: Of 309 early-stage CRC patients, a prognostic immune signature included 23 immune-related genes was constructed. In the training cohort, when considering patients with early tumor stage (I or II), IRGS significantly stratified patients into immune low- vs high-risk groups in terms of disease-free survival (HR = 5.03, 95%CI = 2.94-8.62, P < 0.001). Similarly, higher IRGS was correlated with significantly worse prognosis of early-stage CRC patients in validation-1 (HR = 2.71, 95%CI = 1.44-5.08, P = 0.001) and meta-validation cohort (HR = 3.10, 95%CI = 1.60-6.00, P < 0.001). When compared with Oncotype DX, we found IRGS achieved an improved survival correlation in the training cohort (mean C-index, 0.85 vs 0.65) and the validation-1 cohort (mean C-index, 0.72 vs 0.61). After integrated with clinical characteristics, IRGS remained as an independent prognostic factor after adjusting for T stage and TNM stage of tumor in multivariate analysis (HR = 2.02, 95%CI = 1.61-2.53, P < 0.001). Furthermore, IRGS stratified immune low-risk group patients with adjuvant chemotherapy showed even worse disease-free survival when compared with those without adjuvant chemotherapy (HR = 5.66, 95%CI = 3.153-10.16, P < 0.001 in the training cohort and HR = 3.21, 95%CI = 1.74-5.92, P < 0.001 in the validation-1 cohort). IRGS identified immune high-risk group obtained a significantly higher immune and stromal infiltration (P < 0.001). Particularly, the percentages of Macrophages M2 and CD8+ T cells infiltration were significantly different between these two groups. Conclusions: The proposed prognostic IRGS is a promising system for estimating DFS of colorectal cancer patients, especially those in early-stage. Further studies are needed to evaluate the clinical utility of this system in predicting prognosis of colorectal cancer patients.
Immune-related gene prognostic index (IRGPI) for lung adenocarcinoma predicts patient prognosis and immunotherapy response

Zheng Zhu,Wei Feng,Xiao-Yan Tan,Pin-Chao Gu,Wei Song,Hai-Tao Ma

2023-01-01

Abstract:Objective: We searched for a predictive biomarker that also predicts whether patients would benefit from immune checkpoint blockade (ICB) treatment from a few angles, because existing biomarkers no longer wholly replicate the interconnections of distinctive elements in the tumor microenvironment (TME). Methods: We identified 55 pivotal IRGs by performing a WGCNA and univariate Cox regression analysis on a lung adenocarcinoma dataset from the TCGA database. The IRGPI model was then constructed using multivariate Cox regression analysis, which identified 16 genes and verified the use of the GSE68465 database. The AUC of the IRGPI was compared to those of the current biomarkers to determine its predictive potential. Then we examined the molecular and immunological properties of ICB and assessed its effectiveness using CTLA4 expression and TIDE. Results: Patients with a high IRGPI had a later clinical stage, more severe symptoms, and a worse prognosis. Patients with a low IRGPI had a higher immune escape potential and were less responsive to immunotherapy. Conclusion: The IRGPI may be a biomarker for determining the prognosis of patients and whether they respond favorably to ICB therapy.
Prognostic Significance of Eight Immune-Related Genes on Survival in Patients with Lung Squamous Cell Carcinoma

Hansheng Wu,Shujie Huang,Weitao Zhuang,Guibin Qiao

DOI: https://doi.org/10.2217/bmm-2020-0483

2021-01-01

Biomarkers in Medicine

Abstract:Aim: To build a valid prognostic model based on immune-related genes for lung squamous cell carcinoma (LUSC). Materials & methods: Differential expression of immune-related genes between LUSC and normal specimens from TCGA dataset and underlying molecular mechanisms were systematically analyzed. Constructing and validating the high-risk and low-risk groups for LUSC survival. Results: The immune-related gene-based prognostic index (IRGPI) could predict the overall survival in patients with different clinicopathological characteristics. Functional enrichment analysis of differential expression of immune-related gene signature indicated distinctive molecular pathways between high-risk and low-risk groups. Conclusion: Analysis of IRGs in LUSC enable us to stratify patients into distinct risk groups, which may help to screen LUSC patients at risk and decision making on follow-up therapeutic intervention.
Identifying an immunogenic cell death-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma

Xue Li,Dengfeng Zhang,Pengfei Guo,Shaowei Ma,Shaolin Gao,Shujun Li,Yadong Yuan

DOI: https://doi.org/10.18632/aging.205705

2024-04-03

Abstract:Background: Immunogenic cell death (ICD) is a regulated form of cell death that triggers an adaptive immune response. The objective of this study was to investigate the correlation between ICD-related genes (ICDGs) and the prognosis and the immune microenvironment of patients with lung adenocarcinoma (LUAD). Methods: ICD-associated molecular subtypes were identified through consensus clustering. Subsequently, a prognostic risk model comprising 5 ICDGs was constructed using Lasso-Cox regression in the TCGA training cohort and further tested in the GEO cohort. Enriched pathways among the subtypes were analyzed using GO, KEGG, and GSVA. Furthermore, the immune microenvironment was assessed using ESTIMATE, CIBERSORT, and ssGSEA analyses. Results: Consensus clustering divided LUAD patients into three ICDG subtypes with significant differences in prognosis and the immune microenvironment. A prognostic risk model was constructed based on 5 ICDGs and it was used to classify the patients into two risk groups; the high-risk group had poorer prognosis and an immunosuppressive microenvironment characterized by low immune score, low immune status, high abundance of immunosuppressive cells, and high expression of tumor purity. Cox regression, ROC curve analysis, and a nomogram indicated that the risk model was an independent prognostic factor. The five hub genes were verified by TCGA database, cell sublocalization immunofluorescence analysis, IHC images and qRT-PCR, which were consistent with bioinformatics analysis. Conclusions: The molecular subtypes and a risk model based on ICDGs proposed in our study are both promising prognostic classifications in LUAD, which may provide novel insights for developing accurate targeted cancer therapies.
A Novel Inflammatory-Related Gene Signature Based Model for Risk Stratification and Prognosis Prediction in Lung Adenocarcinoma

Wen-Yu Zhai,Fang-Fang Duan,Si Chen,Jun-Ye Wang,Yao-Bin Lin,Yi-Zhi Wang,Bing-Yu Rao,Ze-Rui Zhao,Hao Long

DOI: https://doi.org/10.3389/fgene.2021.798131

IF: 3.7

2022-01-05

Frontiers in Genetics

Abstract:Inflammation is an important hallmark of cancer and plays a role in both neogenesis and tumor development. Despite this, inflammatory-related genes (IRGs) remain to be poorly studied in lung adenocarcinoma (LUAD). We aim to explore the prognostic value of IRGs for LUAD and construct an IRG-based prognosis signature. The transcriptomic profiles and clinicopathological information of patients with LUAD were obtained from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). Least absolute shrinkage and selection operator (LASSO) analysis and multivariate Cox regression were applied in the TCGA set to generate an IRG risk signature. LUAD cases with from the GSE31210 and GSE30219 datasets were used to validate the predictive ability of the signature. Analysis of the TCGA cohort revealed a five-IRG risk signature consisting of EREG, GPC3, IL7R, LAMP3, and NMUR1. This signature was used to divide patients into two risk groups with different survival rates. Multivariate Cox regression analysis verified that the risk score from the five-IRG signature negatively correlated with patient outcome. A nomogram was developed using the IRG risk signature and stage, with C-index values of 0.687 (95% CI: 0.644–0.730) in the TCGA training cohort, 0.678 (95% CI: 0.586–0.771) in GSE30219 cohort, and 0.656 (95% CI: 0.571–0.740) in GSE30219 cohort. Calibration curves were consistent between the actual and the predicted overall survival. The immune infiltration analysis in the TCGA training cohort and two GEO validation cohorts showed a distinctly differentiated immune cell infiltration landscape between the two risk groups. The IRG risk signature for LUAD can be used to predict patient prognosis and guide individual treatment. This risk signature is also a potential biomarker of immunotherapy.

genetics & heredity
Comprehensive Analysis Reveals the Potential Value of Inflammatory Response Genes in the Prognosis, Immunity, and Drug Sensitivity of Lung Adenocarcinoma

Song Congkuan,Pan Shize,Li Donghang,Hao Bo,Lu Zilong,Lai Kai,Li Ning,Geng Qing

DOI: https://doi.org/10.1186/s12920-022-01340-7

2022-01-01

BMC Medical Genomics

Abstract:BACKGROUND:Although the relationship between inflammatory response and tumor has been gradually recognized, the potential implications of of inflammatory response genes in lung adenocarcinoma (LUAD) remains poorly investigated.METHODS:RNA sequencing and clinical data were obtained from multiple independent datasets (GSE29013, GSE30219, GSE31210, GSE37745, GSE42127, GSE50081, GSE68465, GSE72094, TCGA and GTEx). Unsupervised clustering analysis was used to identify different tumor subtypes, and LASSO and Cox regression analysis were applied to construct a novel scoring tool. We employed multiple algorithms (ssGSEA, CIBERSORT, MCP counter, and ESTIMATE) to better characterize the LUAD tumor microenvironment (TME) and immune landscapes. GSVA and Metascape analysis were performed to investigate the biological processes and pathway activity. Furthermore, 'pRRophetic' R package was used to evaluate the half inhibitory concentration (IC50) of each sample to infer drug sensitivity.RESULTS:We identified three distinct tumor subtypes, which were related to different clinical outcomes, biological pathways, and immune characteristics. A scoring tool called inflammatory response gene score (IRGS) was established and well validated in multiple independent cohorts, which could well divide patients into two subgroups with significantly different prognosis. High IRGS patients, characterized by increased genomic variants and mutation burden, presented a worse prognosis, and might show a more favorable response to immunotherapy and chemotherapy. Additionally, based on the cross-talk between TNM stage, IRGS and patients clinical outcomes, we redefined the LUAD stage, which was called 'IRGS-Stage'. The novel staging system could distinguish patients with different prognosis, with better predictive ability than the conventional TNM staging.CONCLUSIONS:Inflammatory response genes present important potential value in the prognosis, immunity and drug sensitivity of LUAD. The proposed IRGS and IRGS-Stage may be promising biomarkers for estimating clinical outcomes in LUAD patients.
Establishment of Immune-related Gene Pair Signature to Predict Lung Adenocarcinoma Prognosis

Xueping Jiang,Yanping Gao,Nannan Zhang,Cheng Yuan,Yuan Luo,Wenjie Sun,Jianguo Zhang,Jiangbo Ren,Yan Gong,Conghua Xie

DOI: https://doi.org/10.1177/0963689720977131

2020-01-01

Cell Transplantation

Abstract:Tumor microenvironment (TME) has critical impacts on the pathogenesis of lung adenocarcinoma (LUAD). However, the molecular mechanism of TME effects on the prognosis of LUAD patients remains unclear. Our study aimed to establish an immune-related gene pair (IRGP) model for prognosis prediction and internal mechanism investigation. Based on 702 TME-related differentially expressed genes (DEGs) extracted from The Cancer Genome Atlas (TCGA) training cohort using the ESTIMATE algorithm, a 10-IRGP signature was established to predict LUAD patient prognosis. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses showed that DEGs were significantly associated with tumor immune response. In both TCGA training and Gene Expression Omnibus validation datasets, the risk score was an independent prognostic factor for LUAD patients using Lasso-Cox analysis, and patients in the high-risk group had poorer prognosis than those in the low-risk one. In the high-risk group, M2 macrophage and neutrophil infiltrations were higher, while the levels of T cell follicular helpers were significantly lower. The gene set enrichment analysis results showed that DNA repair signaling pathways were involved. In summary, we established an IRGP signature as a potential biomarker to predict the prognosis of LUAD patients.
Additional File 2: of A Large Cohort Study Identifying a Novel Prognosis Prediction Model for Lung Adenocarcinoma Through Machine Learning Strategies

Yin Liu,Di Ge,Jun Gu,Fan Xu,Qinqing Zhu,Lu Chen

DOI: https://doi.org/10.6084/m9.figshare.9776897

2019-01-01

Abstract:Table S1. Clinical information of LUAD patients from TCGA and GEO data repositories (XLSX 269 kb)
Identification of an inflammatory response signature associated with prognostic stratification and drug sensitivity in lung adenocarcinoma

Congkuan Song,Zilong Lu,Kai Lai,Donghang Li,Bo Hao,Chenzhen Xu,Shize Pan,Ning Li,Qing Geng

DOI: https://doi.org/10.1038/s41598-022-14323-6

2022-06-16

Abstract:Increasing evidence has confirmed the close connection between inflammatory response and tumorigenesis. However, the relationship between inflammatory response genes (IRGs) and the prognosis of lung adenocarcinoma (LUAD) as well as the response to drug therapy remains poorly investigated. Here, we comprehensively analyzed IRGs RNA expression profiling and clinical features of over 2000 LUAD patients from 12 public datasets. The Cox regression method and LASSO analysis were combined to develop a novel IRG signature for risk stratification and drug efficacy prediction in LUAD patients. Enriched pathways, tumor microenvironment (TME), genomic and somatic mutation landscape in different subgroups were evaluated and compared with each other. This established IRG signature including 11 IRGs (ADM, GPC3, IL7R, NMI, NMURI, PSEN1, PTPRE, PVR, SEMA4D, SERPINE1, SPHK1), could well categorize patients into significantly different prognostic subgroups, and have better predictive in independently assessing survival as compared to a single clinical factor. High IRG scores (IRGS) patients might benefit more from immunotherapy and chemotherapy. Comprehensive analysis uncovered significant differences in enriched pathways, TME, genomic and somatic mutation landscape between the two subgroups. Additionally, integrating the IRGS and TNM stage, a reliable prognostic nomogram was developed to optimize survival prediction, and validated in an independent external dataset for clinical application. Take together, the proposed IRG signature in this study is a promising biomarker for risk stratification and drug efficacy prediction in LUAD patients. This study may be meaningful for explaining the responses of clinical therapeutic drugs and providing new strategies for administrating sufferer of LUAD.
Identification of Immune Activation-Related Gene Signature for Predicting Prognosis and Immunotherapy Efficacy in Lung Adenocarcinoma

Weibiao Zeng,Jin Wang,Jian Yang,Zhike Chen,Yuan Cui,Qifan Li,Gaomeng Luo,Hao Ding,Sheng Ju,Baisong Li,Jun Chen,Yufeng Xie,Xin Tong,Mi Liu,Jun Zhao

DOI: https://doi.org/10.3389/fimmu.2023.1217590

IF: 7.3

2023-01-01

Frontiers in Immunology

Abstract:BackgroundLung adenocarcinoma (LUAD) is a major subtype of non-small cell lung cancer (NSCLC) with a highly heterogeneous tumor microenvironment. Immune checkpoint inhibitors (ICIs) are more effective in tumors with a pre-activated immune status. However, the potential of the immune activation-associated gene (IAG) signature for prognosis prediction and immunotherapy response assessment in LUAD has not been established. Therefore, it is critical to explore such gene signatures.MethodsRNA sequencing profiles and corresponding clinical parameters of LUAD were extracted from the TCGA and GEO databases. Unsupervised consistency clustering analysis based on immune activation-related genes was performed on the enrolled samples. Subsequently, prognostic models based on genes associated with prognosis were built using the last absolute shrinkage and selection operator (LASSO) method and univariate Cox regression. The expression levels of four immune activation related gene index (IARGI) related genes were validated in 12 pairs of LUAD tumor and normal tissue samples using qPCR. Using the ESTIMATE, TIMER, and ssGSEA algorithms, immune cell infiltration analysis was carried out for different groups, and the tumor immune dysfunction and rejection (TIDE) score was used to evaluate the effectiveness of immunotherapy.ResultsBased on the expression patterns of IAGs, the TCGA LUAD cohort was classified into two clusters, with those in the IAG-high pattern demonstrating significantly better survival outcomes and immune cell infiltration compared to those in the IAG-low pattern. Then, we developed an IARGI model that effectively stratified patients into different risk groups, revealing differences in prognosis, mutation profiles, and immune cell infiltration within the tumor microenvironment between the high and low-risk groups. Notably, significant disparities in TIDE score between the two groups suggest that the low-risk group may exhibit better responses to ICIs therapy. The IARGI risk model was validated across multiple datasets and demonstrated exceptional performance in predicting overall survival in LUAD, and an IARGI-integrated nomogram was established as a quantitative tool for clinical practice.ConclusionThe IARGI can serve as valuable biomarkers for evaluating the tumor microenvironment and predicting the prognosis of LUAD patients. Furthermore, these genes probably provide valuable guidance for establishing effective immunotherapy regimens for LUAD patients.
Identification of an immune-related genes signature in lung adenocarcinoma to predict survival and response to immune checkpoint inhibitors

Zeinab Davoodi-Moghaddam,Farideh Jafari-Raddani,Shahram Kordasti,Davood Bashash

DOI: https://doi.org/10.1186/s43046-024-00236-0

2024-10-07

Abstract:Background: Although advances in immune checkpoint inhibitor (ICI) research have provided a new treatment approach for lung adenocarcinoma (LUAD) patients, their survival is still unsatisfactory, and there are issues in the era of response prediction to immunotherapy. Methods: Using bioinformatics methods, a prognostic signature was constructed, and its predictive ability was validated both in the internal and external datasets (GSE68465). We also explored the tumor-infiltrating immune cells, mutation profiles, and immunophenoscore (IPS) in the low-and high-risk groups. Results: As far as we are aware, this is the first study which introduces a novel prognostic signature model using BIRC5, CBLC, S100P, SHC3, ANOS1, VIPR1, LGR4, PGC, and IGKV4.1. According to multivariate analysis, the 9-immune-related genes (IRGs) signature provided an independent prognostic factor for the overall survival (OS). The low-risk group had better OS, and the tumor mutation burden (TMB) was significantly lower in this group. Moreover, the risk scores were negatively associated with the tumor-infiltrating immune cells, like CD8+ T cells, macrophages, dendritic cells, and NK cells. In addition, the IPS were significantly higher in the low-risk group as they had higher gene expression of immune checkpoints, suggesting that ICIs could be a promising treatment option for low-risk LUAD patients. Conclusion: The combination of these 9-IRGs not only could efficiently predict overall survival of LUAD patients but also show a powerful association with the expression of immune checkpoints and response to ICIs based on IPS; hoping this model paves the way for better stratification and management of patients in clinical practice.
Identification of a Prognostic Model Based on Immune-Related Genes of Lung Squamous Cell Carcinoma

Rui Li,Xiao Liu,Xi-Jia Zhou,Xiao Chen,Jian-Ping Li,Yun-Hong Yin,Yi-Qing Qu

DOI: https://doi.org/10.3389/fonc.2020.01588

IF: 4.7

2020-09-02

Frontiers in Oncology

Abstract:Immune-related genes (IRGs) play considerable roles in tumor immune microenvironment (IME). This research aimed to discover the differentially expressed immune-related genes (DEIRGs) based on the Cox predictive model to predict survival for lung squamous cell carcinoma (LUSC) through bioinformatics analysis. First of all, the differentially expressed genes (DEGs) were acquired based on The Cancer Genome Atlas (TCGA) using the limma R package, the DEIRGs were obtained from the ImmPort database, whereas the differentially expressed transcription factors (DETFs) were acquired from the Cistrome database. Thereafter, a TFs-mediated IRGs network was constructed to identify the candidate mechanisms for those DEIRGs in LUSC at molecular level. Moreover, Gene Ontology (GO), together with Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, was conducted for exploring those functional enrichments for DEIRGs. Besides, univariate as well as multivariate Cox regression analysis was conducted for establishing a prediction model for DEIRGs biomarkers. In addition, the relationship between the prognostic model and immunocytes was further explored through immunocyte correlation analysis. In total, 3,599 DEGs, 223 DEIRGs, and 46 DETFs were obtained from LUSC tissues and adjacent non-carcinoma tissues. According to multivariate Cox regression analysis, 10 DEIRGs (including CALCB, GCGR, HTR3A, AMH, VGF, SEMA3B, NRTN, ENG, ACVRL1, and NR4A1) were retrieved to establish a prognostic model for LUSC. Immunocyte infiltration analysis showed that dendritic cells and neutrophils were positively correlated with IRGs, which possibly exerted an important part within the IME of LUSC. Our study identifies a prognostic model based on IRGs, which is then used to predict LUSC prognosis and analyze immunocyte infiltration. This may provide a novel insight for exploring the potential IRGs in the IME of LUSC.

oncology
Additional File 8 of the Immune Subtypes and Landscape of Sarcomas

Wei‐Hung Weng,Yuling Lin,Zhang Li,Cong Tan,Jiaoyan Lv,I Weng Lao,Wenhuo Hu,Zhenzhong Deng,Zebing Liu,Jian Wang,Ming Xu

DOI: https://doi.org/10.6084/m9.figshare.21202086

2022-01-01

Abstract:Additional file8. Table S5: List of six prognostic genes in the blue module.
Construction and Validation of a Novel Immune-Related Gene Pairs-Based Prognostic Model in Lung Adenocarcinoma

Yafeng Liu,Jiawei Zhou,Jing Wu,Xin Zhang,Jianqiang Guo,Yingru Xing,Jun Xie,Ying Bai,Dong Hu

DOI: https://doi.org/10.1177/10732748221150227

2023-01-01

Cancer Control

Abstract:Object Focus on immune-related gene pairs (IRGPs) and develop a prognostic model to predict the prognosis of patients with lung adenocarcinoma (LUAD). Methods First, the LUAD patient dataset was downloaded from The Cancer Genome Atlas database, and paired analysis of immune-related genes was subsequently conducted. Then, LASSO regression was used to screen prognostic IRGPs for building a risk prediction model. Meanwhile, the Gene Expression Omnibus database was used for external validation of the model. Next, the clinical predictive power of IRGPs features was assessed by uni-multivariate Cox regression analysis, the infiltration of key immune cells in high and low IRGPs risk groups was analyzed with CIBERSORT, quanTIseq, and Timer, and the key pathways enriched for IRGPs were assessed using the Kyoto Encyclopedia of Genes and Genomes. Finally, the expression and related functions of key immune cells and genes were verified by immunofluorescence and cell experiments of tissue samples. Results It was revealed that the risk score of 19 IRGPs could be used as accurate indicators to evaluate the prognosis of LUAD patients, and the risk score was mainly related to T cell infiltration based on CIBERSORT analysis. Two genes of IRGPs, IL6, and CCL2, were found to be closely associated with the expression of PD-1/PD-L1 and the function of T-cells. Depending on the results of tissue immunofluorescence, IL6, CCL2, and T cells were highly expressed in the LUAD tissues of patients. Furthermore, IL6 and CCL2 were positively correlated with the expression of T cells. Besides, qRT-PCR assay in four different LUAD cells proved that IL6 and CCL2 were positively correlated with the expression of PD-L1 (P < .001). Conclusions Based on 19 IRGPs, an effective prognosis model was established to predict the prognosis of LUAD patients. In addition, IL6 and CCL2 are closely related to the function of T-cells.

Additional File 8 of IRGS: an Immune-Related Gene Classifier for Lung Adenocarcinoma Prognosis

Additional File 2 of IRGS: an Immune-Related Gene Classifier for Lung Adenocarcinoma Prognosis

Additional File 1 of Integration of Single-Cell Regulon Atlas and Multi-Omics Data for Prognostic Stratification and Personalized Treatment Prediction in Human Lung Adenocarcinoma

Identification of Immune-Related Gene Signature for Non-Small Cell Lung Cancer Patients with Immune Checkpoint Inhibitors

Prognostic Risk Model of Immune-Related Genes in Colorectal Cancer

Assessing the Prognostic Capability of Immune-Related Gene Scoring Systems in Lung Adenocarcinoma

Additional File 8 of Immune-related Long Non-Coding RNA Signature Identified Prognosis and Immunotherapeutic Efficiency in Bladder Cancer (BLCA)

Immune-related Gene Signature in Predicting Prognosis of Early-Stage Colorectal Cancer Patients.

Immune-related gene prognostic index (IRGPI) for lung adenocarcinoma predicts patient prognosis and immunotherapy response

Prognostic Significance of Eight Immune-Related Genes on Survival in Patients with Lung Squamous Cell Carcinoma

Identifying an immunogenic cell death-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma

A Novel Inflammatory-Related Gene Signature Based Model for Risk Stratification and Prognosis Prediction in Lung Adenocarcinoma

Comprehensive Analysis Reveals the Potential Value of Inflammatory Response Genes in the Prognosis, Immunity, and Drug Sensitivity of Lung Adenocarcinoma

Establishment of Immune-related Gene Pair Signature to Predict Lung Adenocarcinoma Prognosis

Additional File 2: of A Large Cohort Study Identifying a Novel Prognosis Prediction Model for Lung Adenocarcinoma Through Machine Learning Strategies

Identification of an inflammatory response signature associated with prognostic stratification and drug sensitivity in lung adenocarcinoma

Identification of Immune Activation-Related Gene Signature for Predicting Prognosis and Immunotherapy Efficacy in Lung Adenocarcinoma

Identification of an immune-related genes signature in lung adenocarcinoma to predict survival and response to immune checkpoint inhibitors

Identification of a Prognostic Model Based on Immune-Related Genes of Lung Squamous Cell Carcinoma

Additional File 8 of the Immune Subtypes and Landscape of Sarcomas

Construction and Validation of a Novel Immune-Related Gene Pairs-Based Prognostic Model in Lung Adenocarcinoma